How Did Roche’s Diagnostics Division Perform in 1H17?
Diagnostics Division revenue trends
In the first half of 2017, Roche’s (RHHBY) diagnostics division reported revenues of CHF1 5.8 billion, which reflected a ~5.0% rise on a YoY (year-over-year) basis. The immunodiagnostics primarily attributed to revenue growth in the first half of the year.
In the first half of 2017, centralized and point of care diagnostic solutions reported revenues of CHF 3.5 billion, which is an 8.0% rise on a YoY basis. In that period, diabetes care, molecular diagnostics, and tissue diagnostics generated revenues of CHF 962.0 million, CHF 920.0 million, and CHF 485.0 million, respectively, which reflected a ~4.0% fall, a ~2.0% rise, and a ~13.0% rise, respectively, on a YoY basis.
In 2Q17, Roche’s diagnostics division generated revenues of CHF 3.1 billion, which reflected a ~4.0% rise on a YoY basis and an ~11.0% rise on a QoQ (quarter-over-quarter) basis.
Interested in RHHBY? Don't miss the next report.
Receive e-mail alerts for new research on RHHBY
The new generation of diagnostics products is expected to drive Roche’s diagnostics segment’s revenue growth. Roche has made available cobas MRSA/SA (methicillin-resistant Staphylococcus aureus and Staphylococcus aureus) nucleic acid test for utilization on the cobas Liat system for qualitative detection and differentiation of MSRA and SA in all countries accepting the CE (European Conformity) mark.
Roche has also commercialized the Avenio ctDNA (circulating tumor DNA) analysis kit for oncology research.
Diagnostics division geographical revenue trends
In the first half of 2017, the European, Middle Eastern, and African markets for Roche’s diagnostics generated revenues were CHF 2.3 billion, which reflected a ~1.0% rise on a YoY basis. In that period in North America and Japan, diagnostics generated revenues of CHF 1.5 billion and CHF 220.0 million, respectively, which is a ~3.0% and a 2.0% rise on a YoY basis. In Asia-Pacific and Latin America, its diagnostics generated revenues were CHF 1.3 billion and CHF 425.0 million, respectively, which is a 13.0% rise for both regions.
Roche’s peers in the diagnostics market include Abbott Laboratories (ABT), Thermo Fisher Scientific (TMO), Becton Dickinson (BDX), Alere, Danaher, and others. The Vanguard FTSE Developed Markets ETF (VEA) invests ~0.84% of its total portfolio holdings in Roche.
- Swiss franc ↩